Consult To Aspire
Meeting your specific needs with integrity of process

​Trained as a MD, I elected to enter the Biomedical Sciences and accepted a position in the Department of Pediatrics (Neonatology) at the Children’s Hospital of Philadelphia. I later became a recipient of NIH’s National Research Service Award for postdoctoral training at the University of Pennsylvania. After a successful academic career as a biomedical scientist, I joined DJA Global Pharmaceuticals; a Global Regulatory Consultant to the Pharmaceutical, Device & Biotechnology Industries. I later returned to academia, Penn Medicine’s Abramson Cancer Center, a world leader in cancer research, patient care, and education, to be part of the fastest growing field in cancer therapeutics, immunotherapy. 

Immunotherapy has demonstrated remarkable clinical results in a subpopulation of patients with advanced non-small cell lung cancer (NSCLC). The ability to determine which patients are more likely to respond to such therapy has become a critical objective in lung cancer research. To that end several translational and clinical research studies are ongoing at Penn Medicine’s Abramson Cancer Center. As part of the team at Penn, some of my duties include overseeing daily operation and implementation of projects, centered on immunobiology and immunotherapy of lung cancer.

Selected Publications:

Christiana W. Davis MD, Linda W. Gonzales PhD, Roberta A. Ballard MD, Philip L. Ballard MD; Guo Changjiang Guo MD, Andrew J. Gow PhD. Expression of Nitric Oxide Synthases and endogenous NO metabolism in Bronchopulmonary Dysplasia. Pediatric Pulmonology 43:703-709 (2008)

Charu Aggarwal, Christiana W. Davis, Rosemarie Mick, Jeffrey C. Thompson, Saman Ahmed, Seth Jeffries, Stephen Bagley, Peter Gabriel, Tracey L. Evans, Joshua M. Bauml, Christine Ciunci, Evan Alley, Jennifer J. D. Morrissette, Roger B. Cohen, Erica L. Carpenter, and Corey J. Langer. Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non–Small-Cell Lung Cancer. DOI: 10.1200/PO.18.00107 JCO Precision Oncology - published online August 31, 2018

Joshua Bauml, MD; Rosemarie Mick, MS; Christine Ciunci, MD, MSCE; Charu Aggarwal, MD, MPH; Christiana Davis, MD; Linda Miller, RN; Pooja Patel; Evan Alley, MD, PhD; Christina Knepley, CRNP; Faith Mutale, CRNP; Roger B. Cohen, MD; Corey J. Langer, MD. Phase II Study of Pembrolizumab for Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Following Completion of Locally Ablative Therapy. IASLC 19th World Conference on Lung Cancer (2018)

Availability: Please contact me by email at, or by InMail at

Penn Medicine


Related Links

American Medical Writers Association                                                                FDA Guidance, Compliance, & Regulatory Information
FDA Drug Approvals and Databases                                                                  CFR - Code of Federal Regulations Title 21
CMC- Chemistry, Manufacturing, and Controls                                                   RAPS & Regulatory
Clinical                                                                                                 Documents: Good Clinical Practice
Educational Commission for Foreign Medical Graduates                                    United States Medical Licensing Examination
The Medical Science Liaison Society                                                                   News about Medical Malpractice

Contact Us: P.O.Box 34005 Philadelphia, PA. 19101 . Call 215-222-1640 .